International Journal of Antimicrobial Agents, Год журнала: 2024, Номер 64(1), С. 107185 - 107185
Опубликована: Апрель 30, 2024
Язык: Английский
Expert Review of Anti-infective Therapy, Год журнала: 2025, Номер unknown
Опубликована: Янв. 30, 2025
Community-acquired pneumonia (CAP) and hospital-acquired (HAP) are major global health challenges, with high morbidity mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness standard empirical antibiotics, highlighting need for broader-spectrum agents that target also MDR organisms. This review summarizes findings from a PubMed search on use ceftobiprole in CAP HAP. It highlights key features ceftobiprole, including its mechanism action broad spectrum activity against multiple pathogens. Clinical data randomized controlled trials real-world studies underscore non-inferiority to treatments, favorable safety profile clinical cure rates even challenging cases. Ceftobiprole represents valid option patients Its main advantages include activity, making it valuable therapeutic choice treating polymicrobial infections, profile, which makes good candidate elderly comorbidities polypharmacy. Caution is advised at risk ESBL-producing organisms or Pseudomonas aeruginosa where combination therapy recommended. Moreover, drug monitoring recommended improve outcomes, particularly complex conditions.
Язык: Английский
Процитировано
1
Pathogens, Год журнала: 2024, Номер 13(1), С. 88 - 88
Опубликована: Янв. 19, 2024
Antibiotic resistance in Gram-positive pathogens is a relevant concern, particularly the hospital setting. Several antibiotics are now available to treat these drug-resistant pathogens, such as daptomycin, dalbavancin, linezolid, tedizolid, ceftaroline, ceftobiprole, and fosfomycin. However, antibiotic can also affect newer molecules. Overall, this not frequent phenomenon, but it growing concern some settings compromise effectiveness of molecules, leaving few therapeutic options. We reviewed evidence about epidemiology main molecular mechanisms resistance, methicillin-resistant Sthaphylococcus aureus, coagulase-negative staphylococci, vancomycin-resistant Enterococcus faecium, penicillin-resistant Streptococcus pneumoniae. discussed interpretation susceptibility tests when minimum inhibitory concentrations available. focused on risk emergence during treatment, for daptomycin fosfomycin, we strategies that be implemented reduce which lead clinical failure despite appropriate treatment. The judicious use antibiotics, epidemiological surveillance, infection control measures essential preserving efficacy drugs.
Язык: Английский
Процитировано
5
Microorganisms, Год журнала: 2024, Номер 12(4), С. 725 - 725
Опубликована: Апрель 3, 2024
Ceftobiprole is a fifth-generation cephalosporin approved by European and American regulatory agencies for the treatment of community-acquired pneumonia (CAP) hospital-acquired (HAP). administration useful in severe CAP as well HAP where potential to save other β-lactams including carbapenems or linezolid/vancomycin clinical practice. The aim this study was report real-world evidence ceftobiprole patients with single center. In retrospective study, we included 159 HAP: 105 (66%) had 54 (34%) HAP. median age 70 years (IQR 60–77), Charlson Comorbidity Index 5 3–7.5) baseline INCREMENT ESBL score 8 6–11). mostly given combination (77%) carbapenem-sparing strategy (44%). There were no differences mortality between shorter longer duration (<7 days compared ≥7 (HR 1.02, C.I. 0.58–1.77, p = 0.93) first-line 1.00, 0.46–2.17, 0.989) second-line therapy. use real world effective first- strategy. Further studies are needed explore full ceftobiprole, its antimicrobial stewardship programs.
Язык: Английский
Процитировано
3
Expert Opinion on Drug Metabolism & Toxicology, Год журнала: 2025, Номер unknown, С. 1 - 5
Опубликована: Март 3, 2025
Introduction On 3 April 2024, the United States Food and Drug Administration (FDA) approved ceftobiprole medocaril sodium (Zevtera) for injection treatment of adults with acute bacterial skin structure infections (ABSSSI) as well patients Staphylococcus aureus bloodstream three months to less than 18 years old community-acquired pneumonia.
Язык: Английский
Процитировано
0
Expert Review of Anti-infective Therapy, Год журнала: 2025, Номер unknown
Опубликована: Март 31, 2025
Bloodstream infections (BSIs) caused by Staphylococcus aureus are common worldwide, representing one of the most relevant issues in clinical infectious diseases practice. In particular, BSIs methicillin-resistant S. (MRSA-BSI) still today a challenge since mortality burden remains elevated although decades research. The following topics regarding MRSA-BSI were reviewed and discussed resorting to best available evidence retrieved from PubMed/MEDLINE up October 2024: i) epidemiology; ii) microbiology; iii) classification, with focus on complicated not forms; iv) structured approach patient; v) pharmacokinetics pharmacodynamics main antimicrobial options; vi) controversies therapeutic approach. Despite ongoing efforts better stratify manage MRSA-BSI, there is no universally accepted classification system accurately distinguishing between uncomplicated/low risk complicated/high forms. Biomarkers such as interleukin(IL)-10 hold promise order enable more precise stratification, premise for an appropriate treatment plan. There theoretical rationale implementing combination therapy including beta-lactam agent upfront, especially patients considered at higher unfavorable outcomes, but further data necessary, same applies newer adjuvants. Novel microbiological techniques may help guiding duration.
Язык: Английский
Процитировано
0
Antibiotics, Год журнала: 2023, Номер 12(7), С. 1218 - 1218
Опубликована: Июль 21, 2023
Ceftobiprole is a fifth-generation cephalosporin that has been approved in Europe solely for the treatment of community-acquired and nosocomial pneumonia. The objective was to analyze use ceftobiprole medocaril (Cefto-M) Spanish clinical practice patients with infections hospital or outpatient parenteral antimicrobial therapy (OPAT).This retrospective, observational, multicenter study included treated from 1 September 2021 31 December 2022.A total 249 individuals were enrolled, aged 66.6 ± 15.4 years, whom 59.4% male Charlson index four (IQR 2-6), 13.7% had COVID-19, 4.8% an intensive care unit (ICU). most frequent type infection respiratory (55.8%), followed by skin soft tissue (21.7%). Cefto-M administered 67.9% as empirical treatment, which monotherapy 7 days (5-10) 53.8% cases. infection-related mortality 11.2%. highest rates identified ventilator-associated pneumonia (40%) due methicillin-resistant Staphylococus aureus (20.8%) Pseudomonas aeruginosa (16.1%). mortality-related factors age (OR: 1.1, 95%CI (1.04-1.16)), ICU admission 42.02, (4.49-393.4)), sepsis/septic shock 2.94, (1.01-8.54)).In real life, safe antibiotic, comprising only half prescriptions infections, mainly rescue pluripathological severe infectious diseases.
Язык: Английский
Процитировано
7
Infectious Diseases Now, Год журнала: 2023, Номер 54(1), С. 104790 - 104790
Опубликована: Сен. 27, 2023
Язык: Английский
Процитировано
6
Diagnostic Microbiology and Infectious Disease, Год журнала: 2024, Номер 109(3), С. 116263 - 116263
Опубликована: Март 16, 2024
Язык: Английский
Процитировано
2
Expert Opinion on Drug Metabolism & Toxicology, Год журнала: 2023, Номер 19(8), С. 511 - 535
Опубликована: Авг. 3, 2023
Introduction Bone and joint infections (BJIs) are a major health concern causing remarkable morbidity mortality. However, which antimicrobial treatment could be the best according to specific clinical scenarios and/or pharmacokinetic/pharmacodynamic (PK/PD) features remains an unmet need. This multidisciplinary opinion article aims develop evidence-based algorithms for empirical targeted antibiotic therapy of patients affected by BJIs.Areas covered A team four experts had several rounds assessment developing devoted BJIs. literature search was performed on PubMed-MEDLINE (until April 2023) provide evidence supporting therapeutic choices. Four different were structured infection types (i.e. vertebral osteomyelitis, prosthetic infections, infected non-unions other chronic infectious arthritis), need or not surgical intervention revision, isolation clinically relevant bacterial pathogens from blood tissue cultures, PK/PD antibiotics.Expert The proposed based multifaceted approach considering peculiar each (spectrum activity, properties, bone penetration rate, anti-biofilm activity), hopefully helpful in improving outcome
Язык: Английский
Процитировано
5
Expert Opinion on Drug Safety, Год журнала: 2023, Номер 23(1), С. 9 - 36
Опубликована: Дек. 26, 2023
Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) is a major issue in healthcare, since it often associated with endocarditis or deep site foci. Relevant morbidity and mortality MRSA-BSIs forced the development of new antibiotic strategies; particular, this review will focus attention on fifth-generation cephalosporins (ceftaroline/ceftobiprole), that are only ß-lactams active against MRSA.
Язык: Английский
Процитировано
5